iSelect Fund
  • Portfolio
  • Team
  • Focus Areas
    • Food & Agriculture
    • Healthcare
    • Food is Health
    • Soil Health
    • Impact Investing
    • Entrepreneurs
  • Invest
  • Insights
  • Contact
  • My iSelect
    • My iSelect Login
Select Page

Cofactor Genomics begins patient enrolment in NSCLC study of OncoPrism predictive diagnostic assay

Read more

Predictive diagnostics: closing the precision medicine gap

Read more

Cofactor Genomics Unveils New Data Showing Novel OncoPrism Diagnostic is Nearly Twice as Accurate as PD-L1 in Identifying Immunotherapy Responders

Read more

BioGenerator Invests $3.5 Million in 22 St. Louis Bioscience Companies

Read more

Cofactor Genomics, UCSD Partner on Metastatic Head, Neck Cancer Study

Read more

Cofactor Genomics Announces New U.S. Patent Granted for Predictive Immune Modeling Technology

Read more
« Older Entries

Related Posts

  • cancer
    2 Companies That Are Working to Cure Cancer Right Now
  • Cofactor Genomics
    [PODCAST] Cofactor Genomics and the Future of Personalized Medicine
  • Agrible Sustainable Farming
    Agrible: Helping CPGs Leverage Farm-Level Predictive Analytics
  • Gene Editing
    Don’t Worry Dad, We Are Just Editing Our Genes  
  • DNA
    Cofactor Genomics: RNA Is About to Make Personalized Medicine a Reality
AgTechFund BLOG SIDEBAR

(314) 219-8688

7750 Maryland Ave
Box 11826
St. Louis, MO 63105

Crunchbase   Twitter   LinkedIn   Facebook   YouTube

Securities offered through North Capital Private Securities ("NCPS"), Member FINRA/SIPC, located at 623 East Ft. Union Blvd, Suite 101, Salt Lake City, UT 84047. NCPS does not make investment recommendations and no communication, through this website or in any other medium should be construed as a recommendation for any security offered on or off this investment platform.  Please review North Capital’s Form CRS and its background on FINRA’s BrokerCheck.  Investments in private offerings are speculative, illiquid and involve a high degree of risk and those investors who cannot afford to lose their entire investment and who cannot hold an investment for an indeterminate period should not invest in such offerings. Past performance is not indicative of future results.  All information provided herein should not be relied upon to make an investment decision and does not intend to make an offer or solicitation for the sale or purchase of any specific securities, investments, or investment strategies. Prospective investors are recommended to consult with a financial adviser, attorney, accountant, and any other professional that can help you understand and assess the risks associated with an investment opportunity. Investments in startups are highly illiquid and those investors who cannot hold an investment for the long term (at least 5-7 years) should not invest.